CA
CARL.US Carlsmed, Inc.
- Market cap
- USD 469M
- P/E
- -
- P/B
- 6.30x
- ROE
- -55.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CARL.US undervalued?
Graham numberThe Graham number of Carlsmed, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Carlsmed, Inc. fundamental analysis
No fundamental analysis for Carlsmed, Inc. yet.
Carlsmed, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The …
Full company profileCarlsmed, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Carlsmed, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 13.8M | 27.2M | 50.5M | 75.5M |
| Gross Profit | 9.90M | 20.0M | 38.0M | 58.2M |
| Operating Income | -18.6M | -24.1M | -30.6M | -44.0M |
| EBITDA | -18.1M | -22.8M | -27.9M | -26.2M |
| Net Income | -18.9M | -24.3M | -29.6M | -41.9M |
| EPS | -4.25 | -1.46 | -2.08 | -1.54 |
| Balance Sheet | ||||
| Total Assets | 14.0M | 51.8M | 130M | 115M |
| Total Liabilities | 60.2M | 122M | 31.3M | 39.6M |
| Shareholders' Equity | -46.1M | -70.6M | 98.9M | 75.7M |
| Cash & Short-term Investments | 7.22M | 40.1M | 110M | 80.2M |
| Total Debt | 11.4M | 17.2M | 17.4M | 21.8M |
| Cash Flow | ||||
| Operating Cash Flow | -17.5M | -25.5M | -29.0M | -38.7M |
| Capital Expenditure | 135K | 180K | 642K | 644K |
| Free Cash Flow | -17.6M | -25.6M | -29.6M | -39.4M |
| Ratios | ||||
| ROE | - | - | -30.0% | -55.4% |
| ROA | -134.8% | -46.8% | -22.8% | -36.4% |
| Net Profit Margin | -137.2% | -89.3% | -58.7% | -55.6% |
| Debt to Equity | - | - | 0.18x | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Carlsmed, Inc. dividends
Carlsmed, Inc. has not paid dividends in the last 3 fiscal years.
Who owns Carlsmed, Inc.
- Insiders 43.27%
- Institutions 40.91%
- Public & others 15.82%
- Shares outstanding 27.4M
- Free float 15.7M
Top funds holding CARL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Janus Henderson Venture D | 611K | 2.24% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 208K | 0.76% | 0.00% | Oct 2026 |
| SEB Nordamerikafond Småbolag | 197K | 0.72% | -0.52% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 159K | 0.58% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 101K | 0.37% | -7.24% | Sep 2026 |
| Fidelity Small Cap Index | 93.1K | 0.34% | 0.00% | Aug 2026 |
| Adara Smaller Companies | 87.1K | 0.32% | -1.46% | Sep 2026 |
| Dunham Small Cap Growth N | 59.1K | 0.22% | +15.96% | Sep 2026 |
| Buffalo Early Stage Growth Fd | 51.5K | 0.19% | -3.28% | Jun 2026 |
| Vanguard Russell 2000 ETF | 48.9K | 0.18% | +0.10% | Sep 2026 |
| Fidelity Extended Market Index | 48.2K | 0.18% | +31.88% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 44.4K | 0.16% | -0.38% | Oct 2026 |
| Dunham Small Cap Value N | 43.9K | 0.16% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 41.7K | 0.15% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 25.7K | 0.09% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 24.2K | 0.09% | 0.00% | Oct 2026 |
| Russell Inv US Small Cap Equity | 23.5K | 0.09% | -9.24% | Sep 2026 |
| Schwab Small Cap Index | 20.4K | 0.07% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 18.2K | 0.07% | +1,415.30% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 17.7K | 0.06% | 0.00% | Aug 2026 |
Top institutions holding CARL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 1.25M | 4.58% | 0.00% | Jun 2026 |
| Parkman Healthcare Partners LLC | 597K | 2.19% | +14.62% | Jun 2026 |
| BlackRock Inc | 533K | 1.95% | +19.18% | Jun 2026 |
| KCM Capital Inc | 440K | 1.61% | +120.00% | Jun 2026 |
| Pier Capital, LLC | 374K | 1.37% | 0.00% | Jun 2026 |
| Millennium Management LLC | 296K | 1.08% | 0.00% | Jun 2026 |
| Palumbo Wealth Management LLC | 267K | 0.98% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 239K | 0.87% | -13.55% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 225K | 0.82% | -20.61% | Jun 2026 |
| Geode Capital Management, LLC | 205K | 0.75% | +5.94% | Jun 2026 |
| State Street Corp | 133K | 0.49% | +17.03% | Jun 2026 |
| Citadel Advisors Llc | 102K | 0.37% | +128.11% | Jun 2026 |
| AQR Capital Management LLC | 92.2K | 0.34% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 73.4K | 0.27% | +388.09% | Jun 2026 |
| Northern Trust Corp | 64.6K | 0.24% | +18.64% | Jun 2026 |
| The Goldman Sachs Group Inc | 63.1K | 0.23% | +178.85% | Jun 2026 |
| D. E. Shaw & Co LP | 60.4K | 0.22% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 56.9K | 0.21% | +19.53% | Jun 2026 |
| Kornitzer Capital Management Inc | 51.7K | 0.19% | -3.26% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 49.9K | 0.18% | +9.98% | Jun 2026 |
Carlsmed, Inc. company profile
- Company name
- Carlsmed, Inc.
- Ticker
- CARL.US
- Exchange
- USA Stocks
- Listed since
- Jul 23, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 127
- Fiscal year end
- December
- Address
- 1800 Aston Avenue, Carlsbad, CA, United States, 92008
- Phone
- 760 766 1923
- Website
- carlsmed.com
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Carlsmed, Inc. management
10- Mr. Michael John CordonnierCo-Founder, Chairman, CEO & President · born 1977
- Mr. Niall Patrick Casey J.D.Co-Founder, Chief Intellectual Property Officer & Director · born 1977
- Mr. William DurallChief Commercial Officer · born 1964
- Mr. Richard J. HeppenstallChief Financial Officer · born 1971
- Mr. Jeff BertoliniChief Operating Officer
- Mr. Shariq HussainChief Technology Officer
- Ms. Stephanie ZhadkevichVP & Head of Investor Relations
- Ms. Jenifer KamocsayChief Legal Officer & Secretary
- Ms. Jodi Allen Coe M.B.A.Senior Vice President of People & Culture
- Ms. Sharon V. SchulzkiChief Clinical & Market Access Officer · born 1958